Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Liver Cancer Specialty Channel

Liver Cancer
Specialty Channel
News
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
01/19/2024
Allison Casey
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the...
01/19/2024
Oncology
News
01/12/2024
Allison Casey
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective...
01/12/2024
Oncology
News
08/10/2023

Allison Casey 

Allison Casey 
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial,...
08/10/2023
Oncology
News
03/24/2023

Allison Casey

Allison Casey
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis,...
03/24/2023
Oncology
Conference Coverage
01/20/2023
Allison Casey
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular...
01/20/2023
Oncology
News
10/26/2022
Allison Casey
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to...
10/26/2022
Oncology
Quiz
10/17/2022
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was...
10/17/2022
Oncology
News
10/07/2022

Allison Casey

Allison Casey
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort...
10/07/2022
Oncology
News
09/08/2022

Allison Casey

Allison Casey
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial...
09/08/2022
Oncology

Advertisement

News

News
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
05/17/2024
Stephanie Holland
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
01/19/2024
Allison Casey
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the...
01/19/2024
Oncology
News
01/12/2024
Allison Casey
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective study, antiviral therapy is associated with long-term survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular carcinoma who undergo curative resection but is...
According to a retrospective...
01/12/2024
Oncology
News
08/10/2023

Allison Casey 

Allison Casey 
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial, proton beam radiotherapy may be a viable treatment alternative to transarterial chemoembolization for patients with hepatocellular carcinoma.
According to a randomized trial,...
08/10/2023
Oncology
News
03/24/2023

Allison Casey

Allison Casey
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis, patients with NAFLD/NASH-related hepatocellular carcinoma were found to be more likely to have larger tumors and to lack background liver fibrosis.
In this retrospective analysis,...
03/24/2023
Oncology
Conference Coverage
01/20/2023
Allison Casey
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular...
01/20/2023
Oncology
News
10/26/2022
Allison Casey
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma, based on findings from the phase 3 HIMALAYA trial.
The FDA granted approval to...
10/26/2022
Oncology
News
10/07/2022

Allison Casey

Allison Casey
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort of a phase 3 trial, ramucirumab was well-tolerated, and demonstrated meaningful clinical activity for previously-treated patients with hepatocellular carcinoma who had not received sorafenib.
According to an expansion cohort...
10/07/2022
Oncology
News
09/08/2022

Allison Casey

Allison Casey
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial demonstrates that adding transarterial chemoembolization to lenvatinib improves survival and response outcomes vs lenvatinib alone in patients with hepatocellular carcinoma.
Findings from a phase 3 trial...
09/08/2022
Oncology

Interactive Features

Quiz
10/17/2022
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was found to be a potential first-line treatment for patients with hepatocellular carcinoma following radical resection who had not received any prior systemic cancer therapy? Take our quick quiz to find out.
Do you know which option was...
10/17/2022
Oncology
Quiz
09/02/2022
Did cabozantinib plus atezolizumab significantly improve clinically meaningful end points for patients with advanced hepatocellular carcinoma who had not previously received systemic cancer therapy when compared to sorafenib?
Did cabozantinib plus atezolizumab significantly improve clinically meaningful end points for patients with advanced hepatocellular carcinoma who had not previously received systemic cancer therapy when compared to sorafenib?
Did cabozantinib plus...
09/02/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement